SEC Form 4 · accession 0001209191-18-053847

Bionano Genomics, Inc. · BNGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 21, 2018

Accepted (ET)

Oct 3, 2018 · 4:42 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001411690

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 21, 2018	P	3,894	$6.47	A	3,894	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock Warrants (right to buy)^F1,F2	$6.47	Aug 21, 2018	P	3,894	A	—	Aug 21, 2023	Common Stock	3,894	3,894	D
Stock Option (Right to Buy)^F3	$7.77	Oct 1, 2018	A	10,516	A	—	Sep 30, 2028	Common Stock	10,516	10,516	D

F1The price reported in column 4 is a weighted average price. These units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, were purchased in multiple transactions at prices ranging from $6.37 to $6.4971, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units purchased at each separate price within the ranges set forth herein. Units purchased at a price of $6.47 per unit, .
F2September 21, 2018 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine.
F3The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date.